drugset / Trial / NCT04351919
Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+)
Phase 4
Withdrawn
Abderrahmane Mami Hospital
Dacima Consulting · collabEshmoun Clinical Research Center · collab
NaSingle-groupOpen-labelTreatment
Summary
The study will assess the number of patients who become asymptomatic from clinical signs of COVID19 and will assess the efficacy of Hydroxychloroquine (HCQ) and Azithromycine effects on paucisymptomatic patients with ou without co-morbidities
Timeline
- Start
- 2020-05-05
- Primary completion
- 2020-07-15
- Completion
- 2020-07-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azithromycin | Small molecule | 500 mg | — |
| Subject | Hydroxychloroquine | Small molecule | 400 mg | — |
Indications
No indication recorded.